| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 6.58% | Exane BNP Paribas | → $23.5 | Downgrades | Outperform → Neutral |
| 10/18/2023 | 45.12% | Barclays | $24 → $32 | Maintains | Overweight |
| 10/13/2023 | -0.23% | Jefferies | $18 → $22 | Downgrades | Buy → Hold |
| 10/04/2023 | 13.38% | Susquehanna | $22 → $25 | Maintains | Positive |
| 09/20/2023 | 26.98% | BTIG | $23 → $28 | Maintains | Buy |
| 08/16/2023 | 13.38% | Citigroup | $22 → $25 | Maintains | Buy |
| 08/02/2023 | 5.22% | HSBC | $13.8 → $23.2 | Maintains | Buy |
| 08/01/2023 | -11.56% | Kepler Cheuvreux | $19 → $19.5 | Downgrades | Buy → Hold |
| 07/31/2023 | 8.84% | Barclays | $20 → $24 | Maintains | Overweight |
| 07/14/2023 | -0.23% | Citigroup | $20 → $22 | Maintains | Buy |
| 07/14/2023 | -0.23% | Capital One | → $22 | Reinstates | → Overweight |
| 07/11/2023 | -0.23% | JP Morgan | $17 → $22 | Maintains | Overweight |
| 05/01/2023 | -18.37% | Piper Sandler | $19 → $18 | Maintains | Overweight |
| 02/28/2023 | -9.3% | Citigroup | $18 → $20 | Maintains | Buy |
| 02/27/2023 | -9.3% | Barclays | $14 → $20 | Maintains | Overweight |
| 02/24/2023 | -9.3% | Cowen & Co. | $17 → $20 | Maintains | Outperform |
| 02/24/2023 | -18.37% | BTIG | $15 → $18 | Maintains | Buy |
| 01/19/2023 | -31.97% | Benchmark | → $15 | Initiates Coverage On | → Buy |
| 11/18/2022 | -22.9% | Piper Sandler | $13 → $17 | Maintains | Overweight |
| 10/25/2022 | -38.78% | HSBC | → $13.5 | Upgrades | Hold → Buy |
| 10/06/2022 | -36.51% | Barclays | $9 → $14 | Upgrades | Equal-Weight → Overweight |
| 09/21/2022 | -34.24% | Exane BNP Paribas | → $14.5 | Upgrades | Neutral → Outperform |
| 08/25/2022 | -45.58% | Benchmark | → $12 | Initiates Coverage On | → Buy |
| 07/15/2022 | -63.72% | B of A Securities | → $8 | Upgrades | Neutral → Buy |
| 06/23/2022 | -36.51% | Cowen & Co. | $15 → $14 | Maintains | Outperform |
| 02/28/2022 | -54.65% | Kepler Cheuvreux | → $10 | Upgrades | Hold → Buy |
| 12/08/2021 | -59.18% | Jefferies | $8 → $9 | Upgrades | Hold → Buy |
| 11/15/2021 | -65.67% | Societe Generale | → $7.57 | Downgrades | Buy → Hold |
| 10/26/2021 | -54.65% | Piper Sandler | $9.6 → $10 | Upgrades | Neutral → Overweight |
| 04/16/2021 | -61.45% | Morgan Stanley | $8.8 → $8.5 | Maintains | Equal-Weight |
| 04/01/2021 | -45.58% | BTIG | → $12 | Initiates Coverage On | → Buy |
| 03/18/2021 | — | Citigroup | Downgrades | Buy → Neutral | |
| 03/02/2021 | — | Exane BNP Paribas | Initiates Coverage On | → Neutral | |
| 03/01/2021 | -60.09% | Morgan Stanley | → $8.8 | Downgrades | Overweight → Equal-Weight |
| 02/22/2021 | -68.25% | Barclays | $10 → $7 | Downgrades | Overweight → Equal-Weight |
| 02/18/2021 | — | UBS | Downgrades | Buy → Neutral | |
| 02/18/2021 | -62.77% | Kepler Cheuvreux | → $8.21 | Downgrades | Buy → Hold |
| 02/01/2021 | -43.31% | Berenberg | → $12.5 | Downgrades | Buy → Hold |
| 01/29/2021 | -36.96% | Morgan Stanley | $9.8 → $13.9 | Maintains | Overweight |
| 12/10/2020 | -54.2% | HSBC | $9.6 → $10.1 | Downgrades | Buy → Hold |
| 11/09/2020 | -56.46% | HSBC | → $9.6 | Upgrades | Hold → Buy |
| 10/26/2020 | -59.68% | Societe Generale | → $8.89 | Upgrades | Hold → Buy |
| 10/13/2020 | -68.25% | Jefferies | → $7 | Upgrades | Underperform → Hold |
| 10/02/2020 | -65.99% | BMO Capital | → $7.5 | Initiates Coverage On | → Market Perform |
| 08/31/2020 | -55.56% | Morgan Stanley | $9.3 → $9.8 | Maintains | Overweight |
| 08/07/2020 | — | HSBC | Downgrades | Buy → Hold | |
| 05/26/2020 | -53.51% | UBS | $9.5 → $10.25 | Maintains | Buy |
| 05/14/2020 | -72.79% | Jefferies | $7 → $6 | Downgrades | Hold → Underperform |
| 04/27/2020 | -41.04% | Wells Fargo | $18 → $13 | Maintains | Overweight |
| 04/23/2020 | -61.45% | CFRA | $16 → $8.5 | Maintains | Hold |
| 04/16/2020 | -57.82% | Morgan Stanley | $8 → $9.3 | Maintains | Overweight |
| 04/09/2020 | -56.92% | UBS | $30 → $9.5 | Maintains | Buy |
| 04/06/2020 | — | Bernstein | Upgrades | Underperform → Outperform | |
| 03/27/2020 | -63.72% | Piper Sandler | $31 → $8 | Downgrades | Overweight → Neutral |
| 03/26/2020 | -43.31% | Berenberg | → $12.5 | Upgrades | Hold → Buy |
| 03/19/2020 | -54.65% | Barclays | $21 → $10 | Upgrades | Equal-Weight → Overweight |
| 03/18/2020 | -63.72% | Morgan Stanley | $25 → $8 | Maintains | Overweight |
| 02/28/2020 | -27.44% | CFRA | $22 → $16 | Maintains | Hold |
| 01/14/2020 | — | Bernstein | Downgrades | Market Perform → Underperform | |
| 12/11/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 12/06/2019 | -4.76% | Jefferies | $33 → $21 | Downgrades | Buy → Hold |
| 11/22/2019 | 2.04% | Berenberg | $29 → $22.5 | Downgrades | Buy → Hold |
| 11/20/2019 | 49.66% | Deutsche Bank | → $33 | Initiates Coverage On | → Buy |
| 10/23/2019 | 58.73% | JP Morgan | $32 → $35 | Maintains | Overweight |
| 10/11/2019 | 49.66% | Morgan Stanley | $34 → $33 | Maintains | Overweight |
| 09/19/2019 | 54.2% | Morgan Stanley | $36 → $34 | Maintains | Overweight |
| 07/30/2019 | 33.79% | Citigroup | $27.4 → $29.5 | Maintains | Neutral |
| 05/15/2019 | 22.45% | Barclays | $29 → $27 | Maintains | Equal-Weight |
| 04/09/2019 | 26.98% | Wells Fargo | $26 → $28 | Maintains | Outperform |
| 03/22/2019 | — | HSBC | Upgrades | Hold → Buy | |
| 03/11/2019 | — | Goldman Sachs | Initiates Coverage On | → Buy | |
| 01/22/2019 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
| 12/14/2018 | 26.98% | Seaport Global | $26 → $28 | Upgrades | Neutral → Buy |
| 12/13/2018 | 26.98% | BMO Capital | $29 → $28 | Upgrades | Market Perform → Outperform |
| 12/10/2018 | — | Bernstein | Upgrades | Underperform → Market Perform | |
| 11/26/2018 | — | HSBC | Upgrades | Reduce → Hold |
What is the target price for TechnipFMC (FTI)?
The latest price target for TechnipFMC (NYSE: FTI) was reported by Exane BNP Paribas on November 6, 2023. The analyst firm set a price target for $23.50 expecting FTI to rise to within 12 months (a possible 6.58% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TechnipFMC (FTI)?
The latest analyst rating for TechnipFMC (NYSE: FTI) was provided by Exane BNP Paribas, and TechnipFMC downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for TechnipFMC (FTI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TechnipFMC, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TechnipFMC was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating TechnipFMC (FTI) correct?
While ratings are subjective and will change, the latest TechnipFMC (FTI) rating was a downgraded with a price target of $0.00 to $23.50. The current price TechnipFMC (FTI) is trading at is $22.05, which is within the analyst's predicted range.